Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study

20260 citationsJournal Articlegold Open Access

Authors

Sunil S Patel · West Texas Retina Consultants

David S Boyer · Retina Vitreous Associates Medical Group

Anat Loewenstein · Tel Aviv University

Julie Clark · Astellas Pharma (United States)

Liansheng Zhu · Astellas Pharma (United States)

Justin Tang · Astellas Pharma (United States)

Dhaval Desai

Abstract

Coadministration of ACP and ranibizumab in treatment-naïve patients with nAMD was well tolerated across different dosing regimens with no new safety issues based on results from two independent studies.

Topics & Keywords

Retinal Diseases and Treatments Ophthalmology and Visual Impairment Studies Ocular Diseases and Behçet’s Syndrome

Publication Details

Published in: BMJ Open Ophthalmology

Volume 11, Issue 1, pp. e002232-e002232

DOI: 10.1136/bmjophth-2025-002232

Field-Weighted Citation Impact: 0.00

Command Palette

Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study

Authors

Abstract

Topics & Keywords

Publication Details